John H Griffin

List of Publications by Citations

379 papers	17,308 citations	69 h-index	117 g-index
388 ext. papers	18,473 ext. citations	7 avg, IF	6.42 L-index

#	Paper	IF	Citations
379	Deficiency of protein C in congenital thrombotic disease. *Journal of Clinical Investigation*, **1981**, 68, 1370-3	15.9	835
378	The cytoprotective protein C pathway. *Blood*, **2007**, 109, 3161-72	2.2	628
377	Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 10068-73	11.5	585
376	Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. *Nature Medicine*, **2003**, 9, 338-42	50.5	503
375	Endothelial and antithrombotic actions of HDL. *Circulation Research*, **2006**, 98, 1352-64	15.7	475
374	Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. *Journal of Experimental Medicine*, **2007**, 204, 2439-48	16.6	283
373	Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. *Critical Care Medicine*, **2000**, 28, 2209-16	1.4	226
372	Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. *Nature Medicine*, **2006**, 12, 1278-85	50.5	222
371	Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. *Proceedings of the National Academy of Sciences of the United States of America*, **1976**, 73, 2554-8	11.5	220
370	A Single Genetic Origin for a Common Caucasian Risk Factor for Venous Thrombosis. *Blood*, **1997**, 89, 397-402	2.2	215
369	Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. *Neuron*, **2004**, 41, 563-72	13.9	212
368	Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. *Biochemical Journal*, **2003**, 373, 65-70	3.8	201
367	Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). *Proceedings of the National Academy of Sciences of the United States of America*, **1978**, 75, 1998-2002	11.5	195
366	Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. *Nature Medicine*, **2004**, 10, 1379-83	50.5	192
365	Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 7830-5	11.5	183
364	Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. *Circulation*, **2001**, 103, 1799-805	16.7	179
363	High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. *Journal of Clinical Investigation*, **1999**, 103, 219-27	15.9	166

362	Activated protein C. *Journal of Thrombosis and Haemostasis*, **2007**, 5 Suppl 1, 73-80	15.4	165
361	Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. *Blood*, **2012**, 120, 5237-46	2.2	157
360	Activated protein C: biased for translation. *Blood*, **2015**, 125, 2898-907	2.2	156
359	Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. *Journal of Clinical Investigation*, **1980**, 66, 1186-9	15.9	155
358	Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. *Proceedings of the National Academy of Sciences of the United States of America*, **1977**, 74, 4636-40	11.5	151
357	Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E1035-42	11.5	150
356	High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. *Circulation*, **2005**, 112, 893-9	16.7	144
355	Synthesis and Properties of Metalloporphyrin Monolayers and Stacked Multilayers Bound to an Electrode via Site Specific Axial Ligation to a Self-Assembled Monolayer. *Journal of the American Chemical Society*, **1998**, 120, 4478-4487	16.4	144
354	Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. *Blood*, **2004**, 104, 1740-4	2.2	143
353	American College of Medical Genetics consensus statement on factor V Leiden mutation testing. *Genetics in Medicine*, **2001**, 3, 139-48	8.1	141
352	Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. *Journal of Clinical Investigation*, **2009**, 119, 3437-49	15.9	135
351	Protein S binds to and inhibits factor Xa. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 2728-32	11.5	130
350	Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. *Journal of Experimental Medicine*, **1978**, 147, 719-29	16.6	125
349	The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. *Journal of Clinical Investigation*, **1977**, 59, 1167-75	15.9	123
348	Novel Vancomycin Dimers with Activity against Vancomycin-Resistant Enterococci. *Journal of the American Chemical Society*, **1996**, 118, 13107-13108	16.4	122
347	Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. *Circulation*, **1990**, 82, 578-85	16.7	120
346	Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 2801-6	9.4	116
345	Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. *New England Journal of Medicine*, **1994**, 331, 1559-62	59.2	116

344	Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 274-9	11.5	115
343	Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. *Journal of Clinical Investigation*, **1979**, 64, 1056-65	15.9	115
342	Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. *Diabetes*, **2004**, 53, 2804-14	0.9	112
341	The biochemistry and pathophysiology of the contact system of plasma. *Advances in Immunology*, **1982**, 33, 241-306	5.6	112
340	Cytoprotective protein C pathways and implications for stroke and neurological disorders. *Trends in Neurosciences*, **2011**, 34, 198-209	13.3	107
339	Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. *Journal of Biological Chemistry*, **2006**, 281, 20077-84	5.4	107
338	Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. *Blood*, **2003**, 101, 4797-801	2.2	100
337	Recent advances in the understanding of contact activation reactions. *Seminars in Thrombosis and Hemostasis*, **1979**, 5, 254-73	5.3	99
336	Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. *Blood*, **2009**, 113, 2859-66	2.2	98
335	Receptors for high molecular weight kininogen on stimulated washed human platelets. *Biochemistry*, **1984**, 23, 6863-9	3.2	95
334	Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. *Biochemistry*, **1980**, 19, 1151-60	3.2	94
333	Impairments of the protein C system and fibrinolysis in infection-associated stroke. *Stroke*, **1996**, 27, 2005-11	6.7	94
332	Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. *Journal of Biological Chemistry*, **2007**, 282, 33022-33	5.4	92
331	Binding of coagulation factor XI to washed human platelets. *Biochemistry*, **1986**, 25, 3884-90	3.2	91
330	Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. *Journal of Neuroscience*, **2008**, 28, 12788-97	6.6	90
329	High-density lipoprotein and the risk of recurrent venous thromboembolism. *Circulation*, **2007**, 115, 1609-14	16.7	90
328	Protein C anticoagulant and cytoprotective pathways. *International Journal of Hematology*, **2012**, 95, 333-45	2.3	88
327	Cardiolipin is a normal component of human plasma lipoproteins. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 1743-8	11.5	86

326	Purification and characterization of plasma protein C inhibitor. *Thrombosis Research*, **1989**, 55, 369-84	8.2	86
325	Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. *Nature Medicine*, **2012**, 18, 1123-9	50.5	85
324	Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. *Blood*, **2012**, 119, 874-83	2.2	85
323	Steric and Electronic Effects, Enantiospecificity, and Reactive Orientation in DNA Binding/Cleaving by Substituted Derivatives of [SalenMn(III)](+). *Inorganic Chemistry*, **1996**, 35, 4837-4847	5.1	84
322	A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen. *Thrombosis Research*, **1983**, 29, 407-17	8.2	84
321	Plasma Lipoproteins, Hemostasis and Thrombosis. *Thrombosis and Haemostasis*, **2001**, 86, 386-394	7	80
320	Specific DNA cleavage mediated by manganese complex [SalenMn(III)]+. *Journal of Organic Chemistry*, **1993**, 58, 820-822	4.2	80
319	Human factor XII (Hageman factor). *Methods in Enzymology*, **1976**, 45, 56-65	1.7	80
318	Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition. *Blood*, **2017**, 130, 2664-2677	2.2	79
317	Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. *Seminars in Hematology*, **2002**, 39, 197-205	4	77
316	Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. *Journal of Biological Chemistry*, **2000**, 275, 12410-5	5.4	77
315	Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. *Journal of Clinical Investigation*, **2010**, 120, 3167-78	15.9	75
314	Total chemical synthesis of enzymatically active human type II secretory phospholipase A2. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 7845-50	11.5	73
313	Nucleotide and deduced amino acid sequences of the oxidosqualene cyclase from Candida albicans. *Journal of the American Chemical Society*, **1992**, 114, 9711-9713	16.4	72
312	Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. *Thrombosis Research*, **1990**, 59, 593-608	8.2	71
311	Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. *European Journal of Neuroscience*, **2009**, 29, 1119-30	3.5	69
310	Protein S confers neuronal protection during ischemic/hypoxic injury in mice. *Circulation*, **2003**, 107, 1791-6	16.7	68
309	Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 1210-5	5.9	68

308	Molecular assembly in the contact phase of the Hageman factor system. *American Journal of Medicine*, **1979**, 67, 657-64	2.4	66
307	Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. *Thrombosis and Haemostasis*, **2009**, 101, 724-33	7	65
306	A structural model for the prostate disease marker, human prostate-specific antigen. *Protein Science*, **1994**, 3, 2033-44	6.3	65
305	Aprotinin (trasylol) is a competitive inhibitor of activated protein C. *Thrombosis Research*, **1989**, 56, 751-6	8.2	65
304	Activated protein C, protease activated receptor 1, and neuroprotection. *Blood*, **2018**, 132, 159-169	2.2	63
303	Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. *Blood*, **2009**, 113, 5970-8	2.2	63
302	Functional recovery after embolic stroke in rodents by activated protein C. *Annals of Neurology*, **2005**, 58, 474-7	9.4	63
301	Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. *Annals of Neurology*, **2019**, 85, 425-438	9.4	63
300	Activated protein C inhibits neutrophil extracellular trap formation and activation. *Journal of Biological Chemistry*, **2017**, 292, 8616-8629	5.4	62
299	Three-dimensional Model of Coagulation Factor Va Bound to Activated Protein C. *Thrombosis and Haemostasis*, **2000**, 84, 849-857	7	62
298	Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor. *Proceedings of the National Academy of Sciences of the United States of America*, **1990**, 87, 8506-10	11.5	62
297	Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. *Blood*, **2003**, 102, 146-51	2.2	61
296	Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers. *Journal of the American Chemical Society*, **2003**, 125, 6517-31	16.4	60
295	Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. *Journal of Biological Chemistry*, **2002**, 277, 28836-40	5.4	60
294	Clinical studies of protein C. *Seminars in Thrombosis and Hemostasis*, **1984**, 10, 162-6	5.3	60
293	An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. *Stroke*, **2012**, 43, 2444-9	6.7	59
292	Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. *Blood Cells, Molecules, and Diseases*, **2003**, 30, 271-6	2.1	59
291	The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. *FEBS Journal*, **1992**, 208, 171-8		59

290	Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. *Annals of the New York Academy of Sciences*, **1981**, 370, 303-10	6.5	59
289	Generation and phenotypic analysis of protein S-deficient mice. *Blood*, **2009**, 114, 2307-14	2.2	56
288	Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. *Journal of Clinical Investigation*, **1980**, 65, 197-206	15.9	56
287	Activated Protein C Resistance: Molecular Mechanisms. *Thrombosis and Haemostasis*, **1995**, 74, 444-448	7	56
286	Central venous thrombosis after cardiac operations in children. *Journal of Thoracic and Cardiovascular Surgery*, **1996**, 112, 883-9	1.5	55
285	Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. *Circulation*, **1991**, 84, 2454-62	16.7	55
284	Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. *Current Pharmaceutical Design*, **2013**, 19, 7479-85	3.3	55
283	PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. *Blood*, **2018**, 131, 1163-1171	2.2	54
282	3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice. *Nature Medicine*, **2016**, 22, 1050-5	50.5	54
281	Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. *Blood*, **2001**, 97, 1907-14	2.2	53
280	Thrombosis in otherwise well children with the factor V Leiden mutation. *Journal of Pediatrics*, **1996** , 128, 324-8	3.6	53
279	Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2692-6	2.9	52
278	Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. *Protein Science*, **1996**, 5, 1883-9	6.3	52
277	Potent blood coagulant activity of human semen due to prostasome-bound tissue factor. *Biology of Reproduction*, **1997**, 56, 757-63	3.9	50
276	The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. *Blood*, **2000**, 96, 585-593	2.2	49
275	Immunoblotting studies of the molecular forms of protein C in plasma. *Thrombosis Research*, **1988**, 52, 33-43	8.2	49
274	Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation. *Stroke*, **1996**, 27, 1163-6	6.7	49
273	Low protein Z levels and risk of ischemic stroke: differences by diabetic status and gender. *Blood Cells, Molecules, and Diseases*, **2002**, 29, 139-44	2.1	48

272	Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISAQ. *Thrombosis Research*, **1989**, 55, 671-82	8.2	48
271	Arteriovenous Blood Metabolomics: A Readout of Intra-Tissue Metabostasis. *Scientific Reports*, **2015**, 5, 12757	4.9	47
270	Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats. *Stroke*, **2013**, 44, 3529-36	6.7	47
269	Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. *Frontiers in Bioscience - Landmark*, **2006**, 11, 2381-99	2.8	47
268	Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. *Current Pharmaceutical Design*, **2012**, 18, 4215-22	3.3	46
267	Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. *Blood*, **2007**, 109, 3733-40	2.2	46
266	Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. *Journal of Neuroscience*, **2010**, 30, 15521-34	6.6	45
265	An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. *Journal of Neuroscience*, **2013**, 33, 6181-90	6.6	44
264	Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 102-8	15.4	44
263	Inhibition of prothrombinase by human secretory phospholipase A2 involves binding to factor Xa. *Journal of Biological Chemistry*, **1998**, 273, 23764-72	5.4	44
262	Interaction of human plasma kallikrein and its light chain with C1 inhibitor. *Biochemistry*, **1983**, 22, 4860-6	3.2	43
261	Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding mode for FV and FVIII C2 domains. *Blood Cells, Molecules, and Diseases*, **1998**, 24, 448-61	2.1	42
260	General and Efficient Method for the Solution- and Solid-Phase Synthesis of Vancomycin Carboxamide Derivatives. *Journal of Organic Chemistry*, **1995**, 60, 1102-1103	4.2	42
259	EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice. *Blood*, **2015**, 125, 2845-54	2.2	41
258	Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. *Protein Science*, **2002**, 11, 2091-101	6.3	41
257	Protein C inhibitor is expressed in tubular cells of human kidney. *Journal of Clinical Investigation*, **1994**, 94, 2117-24	15.9	40
256	Evidence for the Regulation of Urokinase and Tissue Type Plasminogen Activators by the Serpin, Protein C Inhibitor, in Semen and Blood Plasma. *Thrombosis and Haemostasis*, **1993**, 70, 0989-0994	7	40
255	Cytoprotective-selective activated protein C therapy for ischaemic stroke. *Thrombosis and Haemostasis*, **2014**, 112, 883-92	7	39

254	The promise of protein C. *Blood Cells, Molecules, and Diseases*, **2006**, 36, 211-6	2.1	39
253	Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. *Journal of Pediatrics*, **1986**, 108, 698-701	3.6	39
252	Targeting anticoagulant protein S to improve hemostasis in hemophilia. *Blood*, **2018**, 131, 1360-1371	2.2	38
251	Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 1315-22	15.4	38
250	Sphingolipids as bioactive regulators of thrombin generation. *Journal of Biological Chemistry*, **2004**, 279, 12036-42	5.4	38
249	Identification of distinct sequences in human blood coagulation factor Xa and prothrombin essential for substrate and cofactor recognition in the prothrombinase complex. *Journal of Biological Chemistry*, **2003**, 278, 33312-8	5.4	38
248	Formation of the Fibrin Clot: the Balance of Procoagulant and Inhibitory Factors. *Clinics in Haematology*, **1985**, 14, 281-342		38
247	Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. *FEBS Journal*, **1987**, 164, 637-42		37
246	Conversion of a plant oxidosqualene-cycloartenol synthase to an oxidosqualene-lanosterol cyclase by random mutagenesis. *Biochemistry*, **2002**, 41, 8238-44	3.2	36
245	Electrocatalytic Reduction of Dioxygen by Diruthenium Cofacial Diporphyrins Axially-Bound to a Gold-Supported, Self-Assembled Monolayer. *Inorganic Chemistry*, **1996**, 35, 1751-1752	5.1	35
244	3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. *Journal of Experimental Medicine*, **2019**, 216, 279-293	16.6	35
243	Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor. *FASEB Journal*, **2009**, 23, 2244-53	0.9	34
242	Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. *Journal of Biological Chemistry*, **1995**, 270, 24216-21	5.4	34
241	Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. *Protein Science*, **1994**, 3, 588-99	6.3	34
240	Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: patterns revealed by three-dimensional molecular modelling of mutations of the protease domain. *Proteins: Structure, Function and Bioinformatics*, **1994**, 18, 367-80	4.2	34
239	Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII. *Thrombosis Research*, **1978**, 13, 1049-56	8.2	34
238	Nuclear magnetic resonance studies of a ribonuclease-dinucleoside phosphonate complex and their implications for the mechanism of the enzyme. *Annals of the New York Academy of Sciences*, **1973**, 222, 693-708	6.5	34
237	Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice. *American Journal of Respiratory Cell and Molecular Biology*, **2011**, 45, 632-41	5.7	33

236	Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 11484-9	11.5	33
235	Activated protein C and ischemic stroke. *Critical Care Medicine*, **2004**, 32, S247-53	1.4	33
234	Chemical synthesis and spontaneous folding of a multidomain protein: anticoagulant microprotein S. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 14074-8	11.5	33
233	Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C. *Blood*, **1999**, 94, 895-901	2.2	32
232	Solid-Phase Total Synthesis of Bacitracin A. *Journal of Organic Chemistry*, **1996**, 61, 3983-3986	4.2	32
231	Organ-specific protection against lipopolysaccharide-induced vascular leak is dependent on the endothelial protein C receptor. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 769-76	9.4	31
230	Effect of hyperhomocysteinemia on protein C activation and activity. *Blood*, **2002**, 100, 2108-12	2.2	31
229	Binding site for blood coagulation factor Xa involving residues 311-325 in factor Va. *Journal of Biological Chemistry*, **1998**, 273, 14900-5	5.4	31
228	A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. *Biochemistry*, **1993**, 32, 12656-63	3.2	31
227	Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data. *Blood*, **2015**, 126, 1595-600	2.2	30
226	Brain-specific protein C activation during carotid artery occlusion in humans. *Stroke*, **1999**, 30, 542-5	6.7	30
225	Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. *Blood*, **2016**, 128, 1870-1878	2.2	30
224	Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 1744-50	9.4	29
223	Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. *Protein Science*, **1997**, 6, 132-40	6.3	28
222	Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. *Critical Care*, **2006**, 10, R16	10.8	28
221	Apolipoprotein E Receptor 2 Mediates Activated Protein C-Induced Endothelial Akt Activation and Endothelial Barrier Stabilization. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 518-24	9.4	27
220	Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. *Blood*, **2015**, 126, 2415-23	2.2	27
219	Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. *Journal of Neurochemistry*, **2009**, 109, 116-24	6	27

218	Conformational changes in activated protein C caused by binding of the first epidermal growth factor-like module of protein S. *Biochemical Journal*, **2000**, 349 Pt 3, 757-64	3.8	27
217	C-terminal residues 621-635 of protein S are essential for binding to factor Va. *Journal of Biological Chemistry*, **1999**, 274, 36187-92	5.4	27
216	2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 2143-2151	9.4	26
215	Surface-dependent activation of human factor XII (Hageman factor) by kallikrein and its light chain. *FEBS Journal*, **1985**, 151, 531-8		26
214	The assignment of an exchangeable low-field NH proton resonance of ribonuclease A to the active-site histidine-119. *Biochemistry*, **1973**, 12, 2096-9	3.2	26
213	Complex Formation between Bovine Neurophysin-I and Oxytocin, Vasopressin, and Tripeptide Analogs of Their NH2-terminal Region. *Journal of Biological Chemistry*, **1973**, 248, 7975-7978	5.4	26
212	Detection and Quantitation of Cleaved and Uncleaved High Molecular Weight Kininogen in Plasma by Ligand Blotting with Radiolabeled Plasma Prekallikrein or Factor XI. *Thrombosis and Haemostasis*, **1988**, 59, 151-161	7	26
211	Plasma lipoproteins, hemostasis and thrombosis. *Thrombosis and Haemostasis*, **2001**, 86, 386-94	7	26
210	Interactions and inhibition of blood coagulation factor Va involving residues 311-325 of activated protein C. *Protein Science*, **1993**, 2, 1482-9	6.3	25
209	A Protein S Deficient Family with Portal Vein Thrombosis. *Thrombosis and Haemostasis*, **1985**, 54, 724-724		25
208	Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis. *Blood*, **2019**, 134, 1119-1131	2.2	24
207	Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 363-72	15.4	24
206	Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. *Molecular Neurodegeneration*, **2011**, 6, 13	19	24
205	Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry. *Thrombosis and Haemostasis*, **2008**, 99, 453-5	7	24
204	Cardiopulmonary bypass and activation of antithrombotic plasma protein C. *Journal of Thoracic and Cardiovascular Surgery*, **1999**, 118, 422-9; discussion 429-31	1.5	24
203	Complexes of activated protein C with alpha 1-antitrypsin in normal pregnancy and in severe preeclampsia. *American Journal of Obstetrics and Gynecology*, **1991**, 164, 1310-6	6.4	24
202	Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation. *Blood*, **2015**, 126, 2247-53	2.2	23
201	Protein S, an antithrombotic factor, is synthesized and released by neural tumor cells. *Journal of Neurochemistry*, **1993**, 61, 344-7	6	23

200	Dermatan Sulfate and LMW Heparin Enhance the Anticoagulant Action of Activated Protein C. *Thrombosis and Haemostasis*, **1999**, 82, 1462-1468	7	23
199	Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. *Brain Research*, **2013**, 1507, 97-104	3.7	22
198	Prothrombin residues 473-487 contribute to factor Va binding in the prothrombinase complex. *Journal of Biological Chemistry*, **2004**, 279, 49019-25	5.4	22
197	Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein C cleavage site. *Journal of Biological Chemistry*, **2007**, 282, 21848-55	5.4	21
196	Generation of activated protein C during thrombolysis. *Lancet, The*, **1993**, 342, 1275-6	40	21
195	Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. *Journal of Clinical Investigation*, **1997**, 99, 2655-63	15.9	21
194	Activated protein C promotes neuroprotection: mechanisms and translation to the clinic. *Thrombosis Research*, **2016**, 141 Suppl 2, S62-4	8.2	21
193	Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke. *Frontiers in Cellular Neuroscience*, **2015**, 9, 344	6.1	20
192	Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2009**, 1791, 206-11	5	20
191	The Carbohydrate Moiety of Factor V Modulates Inactivation by Activated Protein C. *Blood*, **1997**, 89, 4348-4354	2.2	20
190	Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 935-8	15.4	20
189	Enhanced specificity of immunoblotting using radiolabeled antigen overlay: studies of blood coagulation factor XII and prekallikrein in plasma. *Analytical Biochemistry*, **1986**, 156, 118-25	3.1	20
188	Studies on human protein C inhibitor in normal and Factor V/VIII deficient plasmas. *Thrombosis Research*, **1984**, 36, 197-203	8.2	20
187	Rabbit blood coagulation factor XI. Purification and properties. *Thrombosis Research*, **1979**, 15, 475-86	8.2	20
186	Hormonal interactions at the molecular level: A high resolution proton magnetic resonance study of bovine neurophysins and their interactions with oxytocin. *FEBS Letters*, **1972**, 25, 282-286	3.8	20
185	The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. *Blood*, **2000**, 96, 585-593	2.2	20
184	Coagulation pathways in atherothrombosis. *Trends in Cardiovascular Medicine*, **2002**, 12, 317-24	6.9	19
183	Cardiolipin enhances protein C pathway anticoagulant activity. *Blood Cells, Molecules, and Diseases*, **2000**, 26, 115-23	2.1	19

182	Analysis of protein S C4b-binding protein interactions by homology modeling and inhibitory antibodies. *Biochemistry*, **1994**, 33, 11073-8	3.2	19
181	Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus. *American Journal of Hematology*, **1978**, 4, 401-7	7.1	19
180	Species-specific anticoagulant and mitogenic activities of murine protein S. *Haematologica*, **2009**, 94, 1721-31	6.6	18
179	Chemical synthesis of human protein S thrombin-sensitive module and first epidermal growth factor module. *Biopolymers*, **1998**, 46, 53-63	2.2	18
178	Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human- and bovine-activated protein C with negatively charged phospholipid vesicles. *Journal of Biological Chemistry*, **2003**, 278, 14614-21	5.4	18
177	Design, synthesis and in vitro evaluation of pyridinium ion based cyclase inhibitors and antifungal agents. *Bioorganic and Medicinal Chemistry*, **1996**, 4, 97-103	3.4	18
176	Identification of new inhibitors of protein kinase R guided by statistical modeling. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4108-14	2.9	17
175	Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. *Circulation*, **2002**, 106, 842-6	16.7	17
174	Involvement of amino acid residues 423-429 of human protein S in binding to C4b-binding protein. *Blood Cells, Molecules, and Diseases*, **1998**, 24, 101-12; discussion 113	2.1	17
173	The effect of tryptase from human mast cells on human prekallikrein. *Biochemical and Biophysical Research Communications*, **1985**, 129, 76-81	3.4	17
172	Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa. *Thrombosis and Haemostasis*, **2016**, 115, 551-61	7	17
171	Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **2010**, 37, 17-23		16
170	A novel ELISA for mouse activated protein C in plasma. *Journal of Immunological Methods*, **2006**, 314, 174-81	2.5	16
169	Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va. *Proteins: Structure, Function and Bioinformatics*, **2004**, 54, 433-41	4.2	16
168	Activated protein C reduces graft neutrophil activation in clinical renal transplantation. *American Journal of Transplantation*, **2005**, 5, 2204-12	8.7	16
167	Carbon-13 nuclear magnetic resonance studies of the binding of selectively 13C-enriched oxytocins to the neurophypophyseal protein, bovine neurophysin II. *Biochemistry*, **1977**, 16, 4194-8	3.2	16
166	The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia. *Stem Cells*, **2018**, 36, 796-806	5.8	15
165	Activated protein C and inflammation in human myocardium after heart surgery. *American Journal of Hematology*, **2001**, 67, 210-2	7.1	15

164	Activated protein C-dependent and -independent anticoagulant activities of protein S have different structural requirements. *Blood Cells, Molecules, and Diseases*, **2002**, 29, 190-9	2.1	15
163	Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506-factor V. *Thrombosis Research*, **1995**, 80, 441-3	8.2	15
162	Interactions of Bovine Neurophysin II with Oxytocin and [8-Lysine] Vasopressin. *Journal of Biological Chemistry*, **1974**, 249, 6895-6900	5.4	15
161	COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 506-509	5.1	14
160	Activation of protein C and hemodynamic recovery after coronary artery bypass surgery. *Journal of Thoracic and Cardiovascular Surgery*, **2007**, 133, 44-51	1.5	14
159	Protein C pathway impairment in nonsymptomatic cigarette smokers. *Blood Cells, Molecules, and Diseases*, **2002**, 29, 73-82	2.1	14
158	Carbon-13 nuclear magnetic resonance studies on (85 per cent 13C-enriched Gly 9) oxytocin. *FEBS Letters*, **1975**, 50, 168-71	3.8	14
157	Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency. *Journal of Clinical Investigation*, **1986**, 78, 170-6	15.9	14
156	Interaction of Plasma Kallikrein with Protein C Inhibitor in Purified Mixtures and in Plasma. *Thrombosis and Haemostasis*, **1991**, 65, 046-051	7	14
155	Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding. *Pharmaceutical Research*, **2016**, 33, 1517-26	4.5	13
154	The thrombin-sensitive region of protein S mediates phospholipid-dependent interaction with factor Xa. *Journal of Biological Chemistry*, **2008**, 283, 33046-52	5.4	13
153	Activation of protein C during reperfusion in clinical liver transplantation. *Transplantation*, **2003**, 75, 467-72	1.8	13
152	Factor Va increases the affinity of factor Xa for prothrombin: a binding study using a novel photoactivable thiol-specific fluorescent probe. *Chemistry and Biology*, **2002**, 9, 485-94		13
151	Neutral glycosphingolipid-dependent inactivation of coagulation factor Va by activated protein C and protein S. *Journal of Biological Chemistry*, **2002**, 277, 8861-5	5.4	13
150	Comparative modeling of the three CP modules of the beta-chain of C4BP and evaluation of potential sites of interaction with protein S. *Protein Engineering, Design and Selection*, **1995**, 8, 1253-8	1.9	13
149	Resistance to activated protein C: a common inherited cause of venous thrombosis. *Annals of Vascular Surgery*, **1996**, 10, 174-7	1.7	13
148	Studies of bovine neurophysin-neurohypophyseal hormone interactions. *Annals of the New York Academy of Sciences*, **1975**, 248, 463-79	6.5	13
147	Design of a DNA-Programmed Plasminogen Activator. *Journal of the American Chemical Society*, **2018**, 140, 15516-15524	16.4	13

146	An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C. *PLoS ONE*, **2014**, 9, e104304	3.7	12
145	Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms. *Thrombosis Research*, **1999**, 93, 265-9	8.2	12
144	Competition of activated protein C and urokinase for a heparin-dependent inhibitor. *FASEB Journal*, **1988**, 2, 2263-7	0.9	12
143	Re-evaluation of the anticoagulant properties of high-density lipoprotein-brief report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 570-2	9.4	11
142	FVIIa (Factor VIIa) Induces Biased Cytoprotective Signaling in Mice Through the Cleavage of PAR (Protease-Activated Receptor)-1 at Canonical Arg41 (Arginine41) Site. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 1275-1288	9.4	11
141	Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation. *Frontiers in Neuroscience*, **2020**, 14, 333	5.1	11
140	SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 1586-1594	5.1	11
139	Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C. *Neuropharmacology*, **2018**, 134, 293-301	5.5	11
138	Elevated serum amyloid A is associated with venous thromboembolism. *Thrombosis and Haemostasis*, **2013**, 109, 358-9	7	11
137	Alternative pathways of thromboplastin-dependent activation of human factor X in plasma. *Annals of the New York Academy of Sciences*, **1981**, 370, 325-35	6.5	11
136	Oral anticoagulation reduces activated protein C less than protein C and other vitamin K-dependent clotting factors. *Blood*, **2002**, 100, 4232-3	2.2	10
135	Platelet-coagulant protein interactions in contact activation. *Annals of the New York Academy of Sciences*, **1981**, 370, 241-52	6.5	10
134	Plasma cholesteryl ester transfer protein and blood coagulability. *Thrombosis and Haemostasis*, **2007**, 98, 1160-1164	7	10
133	Molecular interaction site on procoagulant myosin for factor Xa-dependent prothrombin activation. *Journal of Biological Chemistry*, **2019**, 294, 15176-15181	5.4	10
132	Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects. *Shock*, **2019**, 52, 554-555	3.4	10
131	Novel exomic rare variants associated with venous thrombosis. *British Journal of Haematology*, **2020**, 190, 783-786	4.5	10
130	Incorporation of disulfide containing protein modules into multivalent antigenic conjugates: generation of antibodies against the thrombin-sensitive region of murine protein S. *Journal of the American Chemical Society*, **2012**, 134, 19318-21	16.4	9
129	Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. *Blood Cells, Molecules, and Diseases*, **2013**, 51, 104-8	2.1	9

128	Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates. *British Journal of Haematology*, **2006**, 132, 197-203	4.5	9
127	Upregulation of the antithrombotic protein C pathway at birth. *Pediatric Hematology and Oncology*, **1998**, 15, 489-99	1.7	9
126	Immunoblotting studies of coagulation factor XII, plasma prekallikrein, and high molecular weight kininogen. *Seminars in Thrombosis and Hemostasis*, **1987**, 13, 106-14	5.3	9
125	Rabbit blood coagulation factor XI. Mechanism of activation of rabbit Hageman factor (factor XII). *Thrombosis Research*, **1979**, 15, 487-95	8.2	9
124	Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus. *Blood*, **2020**, 135, 1969-1982	2.2	9
123	Quantitative Immunoblotting of Plasma and Platelet Protein S. *Thrombosis and Haemostasis*, **1986**, 56, 382-386	7	9
122	□-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:□M Levels Are Associated with Venous Thromboembolism. *Thrombosis and Haemostasis*, **2018**, 118, 630-638	7	8
121	Regulation of immune cell signaling by activated protein C. *Journal of Leukocyte Biology*, **2018**, 103, 1197	6.5	8
120	Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk. *Research and Practice in Thrombosis and Haemostasis*, **2017**, 1, 93-102	5.1	8
119	Activated protein C correlates inversely with thrombin levels in resting healthy individuals. *American Journal of Hematology*, **1997**, 56, 29-31	7.1	8
118	Graft protein C entrapment is associated with reduced phagocyte activation during reperfusion in human liver transplantation. *Critical Care Medicine*, **2006**, 34, 426-32	1.4	8
117	Elevated plasma fibronectin levels associated with venous thromboembolism. *Thrombosis and Haemostasis*, **2008**, 100, 224-228	7	8
116	Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C. *Thrombosis and Haemostasis*, **2009**, 101, 55-61	7	8
115	Functional Assays for Protein C Activity and Protein C Inhibitor Activity in Plasma. *Thrombosis and Haemostasis*, **1989**, 61, 086-092	7	8
114	Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently. *Circulation Research*, **2021**, 128, 513-529	15.7	8
113	Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 901-913	9.4	7
112	Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases. *Research and Practice in Thrombosis and Haemostasis*, **2017**, 1, 33-40	5.1	7
111	Warfarin untargeted metabolomics study identifies novel procoagulant ethanolamide plasma lipids. *British Journal of Haematology*, **2014**, 165, 409-12	4.5	7

110	Infrared fluorescence for vascular barrier breach in vivo--a novel method for quantitation of albumin efflux. *Thrombosis and Haemostasis*, **2012**, 108, 981-91	7	7
109	Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 2509-17	9.4	7
108	Factor Va residues 311-325 represent an activated protein C binding region. *Journal of Biological Chemistry*, **2007**, 282, 28353-28361	5.4	7
107	Cholesteryl ester transfer protein genotypes associated with venous thrombosis and dyslipoproteinemia in males. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2080-2	15.4	7
106	Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II. *British Journal of Haematology*, **2002**, 117, 676-84	4.5	7
105	Sulfatide bilayers as a surface for contact activation in human plasma. *Biochemical and Biophysical Research Communications*, **1987**, 149, 1002-7	3.4	7
104	Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells. *Blood*, **2019**, 134, 776-781	2.2	6
103	Inhibition of thrombin generation in human plasma by phospholipid transfer protein. *Thrombosis Journal*, **2015**, 13, 24	5.6	6
102	Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant anticoagulant activity. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 2059-62	15.4	6
101	Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation. *Thrombosis and Haemostasis*, **2013**, 110, 275-82	7	6
100	Protective Effect of Activated Protein C in Murine Endotoxemia: Mechanism of Action.. *Blood*, **2005**, 106, 26-26	2.2	6
99	Mechanisms for Mortality Reduction by Activated Protein C in Severe Sepsis.. *Blood*, **2006**, 108, 1-1	2.2	6
98	Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism. *Journal of Atherosclerosis and Thrombosis*, **2016**, 23, 1159-1167	4	6
97	Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 7-19	15.4	6
96	Antibody SPC-54 provides acute in vivo blockage of the murine protein C system. *Blood Cells, Molecules, and Diseases*, **2013**, 50, 252-8	2.1	5
95	Activated protein C in the cardioplegic solution on a porcine model of coronary ischemia-reperfusion has deleterious hemodynamic effects. *Cardiovascular Drugs and Therapy*, **2006**, 20, 113-21	3.9	5
94	Correlations among the DNA binding/cleaving specificities of small molecules revealed by double-strand affinity cleaving. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 73-76	2.9	5
93	Evolution of Sterol and Triterpene Cyclases. *ACS Symposium Series*, **1994**, 44-54	0.4	5

92	Possible Structural Implications of 20 Mutations in the Protein C Protease Domain. *Thrombosis and Haemostasis*, **1994**, 72, 869-873	7	5
91	A Two-Allele Polymorphism in Protein C Inhibitor with Varying Frequencies in Different Ethnic Populations. *Thrombosis and Haemostasis*, **1996**, 75, 062-069	7	5
90	Activated protein C anticoagulant activity is enhanced by skeletal muscle myosin. *Haematologica*, **2020**, 105, e424-e427	6.6	5
89	Physiological cerebrovascular remodeling in response to chronic mild hypoxia: A role for activated protein C. *Experimental Neurology*, **2016**, 283, 396-403	5.7	5
88	PAR1 regulation of CXCL1 expression and neutrophil recruitment to the lung in mice infected with influenza A virus. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 1103-1111	15.4	5
87	Plasma cholesteryl ester transfer protein and blood coagulability. *Thrombosis and Haemostasis*, **2007**, 98, 1160-4	7	5
86	Neuroprotection and vasculoprotection using genetically targeted protease-ligands. *Brain Research* , **2019**, 1715, 13-20	3.7	4
85	Association of Apo(a)isoform size with dyslipoproteinemia in male venous thrombosis patients. *Clinica Chimica Acta*, **2010**, 411, 1279-83	6.2	4
84	High molecular weight kininogen receptor. *Methods in Enzymology*, **1992**, 215, 369-82	1.7	4
83	Chapter 5A Initiation mechanisms: The contact activation system in plasma. *New Comprehensive Biochemistry*, **1986**, 103-128		4
82	Drug-biomolecule interactions: proton magnetic resonance studies of complex formation between bovine neurophysins and oxytocin at molecular level. *Journal of Pharmaceutical Sciences*, **1975**, 64, 507-11	3.9	4
81	Elevated plasma fibronectin levels associated with venous thromboembolism. *Thrombosis and Haemostasis*, **2008**, 100, 224-8	7	4
80	Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect. *Blood*, **2021**, 137, 3428-3442	2.2	4
79	Plasma skeletal muscle myosin phenotypes identified by immunoblotting are associated with pulmonary embolism occurrence in young adults. *Thrombosis Research*, **2020**, 189, 88-92	8.2	4
78	Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S. *Blood Advances*, **2017**, 1, 1423-1426	7.8	3
77	Enantiotracin. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 2239-40	2.9	3
76	Exonic polymorphisms in the protein C gene: interethnic comparison between Caucasians and Asians. *Human Genetics*, **1994**, 94, 177-8	6.3	3
75	Effects of subperineurial injections of very-long-chain and medium-chain fatty acids into rat sciatic nerve. *Neurochemical Pathology*, **1986**, 5, 71-83		3

74	Anti-Inflammatory and Anti-Apoptotic Activities of Activated Protein C Are Independent of Anticoagulant Activity.. *Blood*, **2006**, 108, 65-65	2.2	3
73	Reversal of Novel Oral Anticoagulant (NOAC)-Induced Bleeding in Mice By Engineered superfactor Va. *Blood*, **2014**, 124, 695-695	2.2	3
72	Activated protein C and PAR1-derived and PAR3-derived peptides are anti-inflammatory by suppressing macrophage NLRP3 inflammasomes. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 269-280	15.4	3
71	Removal of Coagulation Factors by the Gamunex -C Purification Process. *Journal of Allergy and Clinical Immunology*, **2013**, 131, AB10	11.5	2
70	Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex. *PLoS ONE*, **2015**, 10, e0135025	3.7	2
69	Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism. *Thrombosis Research*, **2012**, 129, 502-7	8.2	2
68	Cholesterol enhances phospholipid-dependent activated protein C anticoagulant activity. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 340-5	15.4	2
67	Anticoagulant Dysfunction of Human Arg352Trp-Activated Protein C Caused by Defective Factor Va Inactivation. *Thrombosis and Haemostasis*, **2001**, 85, 274-279	7	2
66	Circulating activated protein C in subjects with heterozygous Gln506-factor V. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1998**, 28, 31-6		2
65	Application of nuclear magnetic resonance spectroscopy to proteins. *Biochimie*, **1975**, 57, 453-60	4.6	2
64	Exome Genotyping Links Venous Thrombosis Risk with the Skeletal Muscle Myosin Gene Cluster and Leads to Discovery of New Family of Procoagulant Factors. *Blood*, **2015**, 126, 763-763	2.2	2
63	Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. *Journal of Experimental Medicine*, **2022**, 219,	16.6	2
62	An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms. *Blood Advances*, **2020**, 4, 3716-3727	7.8	2
61	Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation. *Frontiers in Neurology*, **2021**, 12, 593582	4.1	2
60	Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids. *Blood*, **2021**, 137, 1839-1842	2.2	2
59	Sex-dependent effects of genetic upregulation of activated protein C on delayed effects of acute radiation exposure in the mouse heart, small intestine, and skin. *PLoS ONE*, **2021**, 16, e0252142	3.7	2
58	Activation-resistant homozygous protein C R229W mutation causing familial perinatal intracranial hemorrhage and delayed onset of thrombosis. *Thrombosis Research*, **2016**, 143, 17-21	8.2	2
57	C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 1027-1038	15.4	1

56	Gain in translation: heme oxygenase-1 induced by activated protein C promotes thrombus resolution. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 90-2	15.4	1
55	Is adiponectin implicated in venous thromboembolism?. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 1151-2	15.4	1
54	Skeletal muscle myosin promotes coagulation by binding factor XI via its A3 domain and enhancing thrombin-induced factor XI activation.. *Journal of Biological Chemistry*, **2022**, 101567	5.4	1
53	Molecular Interaction Site on Procoagulant Skeletal Muscle Myosin for Factor Xa-Dependent Prothrombin Activation. *Blood*, **2019**, 134, 3622-3622	2.2	1
52	Risk of Recurrent Venous Thromboembolism Reduced by High Density Lipoproteins.. *Blood*, **2006**, 108, 271-271	2.2	1
51	Plasma High Density Lipoprotein and Anticoagulant Response to Activated Protein C (APC) and Protein S. *Blood*, **2011**, 118, 2249-2249	2.2	1
50	Non-Canonical Cleavage of Protease Activated Receptor 1 (PAR1) by Activated Protein C Provides Novel Insights Into the Repertoire of Cytoprotective and Proinflammatory PAR1 Signaling. *Blood*, **2011**, 118, 534-534	2.2	1
49	Factor V Inhibits PAR2-Mediated Lethal Inflammation. *Blood*, **2012**, 120, 3360-3360	2.2	1
48	Synergistic Effect in Bleed Reduction By superfva and Recombinant Human FVIIa in Vivo Suggests a Novel Bypassing Strategy for Hemophilia Patients with Inhibitors. *Blood*, **2014**, 124, 692-692	2.2	1
47	Whole Blood Thromboelastogram Assays Demonstrate Prolonged Factor VIIIa Potency for Recombinant Disulfide Bond-Stabilized Factor VIII Variants.. *Blood*, **2004**, 104, 2976-2976	2.2	1
46	Blocking Protein S Improves Hemostasis in Hemophilia a and B. *Blood*, **2016**, 128, 79-79	2.2	1
45	Plasma Serum Amyloid A Levels Are Increased In Venous Thrombosis Patients and Are Correlated with Blood Coagulability. *Blood*, **2010**, 116, 155-155	2.2	1
44	Insight in Protein S Deficiency From Mouse Models. *Blood*, **2011**, 118, 529-529	2.2	1
43	Skeletal muscle myosin and cardiac myosin attenuate heparin‐antithrombin-dependent anticoagulant activity. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 470-477	15.4	1
42	3K3A-Activated Protein C Protects the Blood-Brain Barrier and Neurons From Accelerated Ischemic Injury Caused by Pericyte Deficiency in Mice.. *Frontiers in Neuroscience*, **2022**, 16, 841916	5.1	1
41	Full-length plasma skeletal muscle myosin isoform deficiency is associated with coagulopathy in acutely injured patients.. *Journal of Thrombosis and Haemostasis*, **2022**,	15.4	1
40	Serum amyloid A4 is a procoagulant apolipoprotein that it is elevated in venous thrombosis patients. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 217-223	5.1	0
39	Reduction Of Histone H1 Cytotoxicity By Activated Protein C and Its Exosite Variants. *Blood*, **2013**, 122, 2334-2334	2.2	0

38	The function of the heavy and light chain of human plasma kallikrein in the activation of factor XII. *Advances in Experimental Medicine and Biology*, **1986**, 198 Pt B, 27-34	3.6	0
37	Addendum: American College of Medical Genetics consensus statement on factor V Leiden mutation testing. *Genetics in Medicine*, **2021**, 23, 2463	8.1	0
36	An optimized method for the isolation of urinary extracellular vesicles for molecular phenotyping: detection of biomarkers for radiation exposure.. *Journal of Translational Medicine*, **2022**, 20, 199	8.5	0
35	3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. *Stroke*, **2020**, 51, 2236-2239	6.7	
34	Causes of thrombophilia yet to be discovered: a personal view. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **2000**, 30 Suppl 2, 26-33		
33	Anticoagulant response to activated protein C: method validation and assay comparison. *Journal of Clinical Laboratory Analysis*, **1995**, 9, 418-23	3	
32	MECHANISMS FOR THE CONVERSION OF BLOOD COAGULATION PROENZYMES TO ENZYMES **1983** , 201-224		
31	Skeletal Muscle Myosin Is Procoagulant By Binding Factor XI Via Its A3 Domain and Enhancing Factor XI Activation By Thrombin. *Blood*, **2021**, 138, 441-441	2.2	
30	Sars-Cov-2 Infection Promotes Endothelial Dysfunction and Thrombosis in a Mouse Model of COVID-19. *Blood*, **2021**, 138, 999-999	2.2	
29	Factor Xa Binding Sites on Factor Va in the Prothrombinase Complex.. *Blood*, **2004**, 104, 1713-1713	2.2	
28	Targeted Replacement of the Murine Thrombomodulin Gene with Human Thrombomodulin Coding Sequence Results in Decreased Protein C Activation and Enhanced Thrombotic Response to Photochemical Injury.. *Blood*, **2004**, 104, 2980-2980	2.2	
27	Sustained Pharmacological Activation of Protein C (PC) in Baboons.. *Blood*, **2004**, 104, 3499-3499	2.2	
26	Activated Protein C Light Chain Mutations Distinguish Exosite Residue Requirements for Anticoagulant Versus Cytoprotective Activities.. *Blood*, **2005**, 106, 29-29	2.2	
25	Efficient Barrier Protective Signaling by Activated Protein C Is Mechanistically Linked to Protein C Activation on Endothelial Cells.. *Blood*, **2005**, 106, 28-28	2.2	
24	Platelet Factor 4 (PF4) Modulation of Endothelial Protein C Receptor and Thrombomodulin Enhancements of Protein C Activation and TAFI Activation by Thrombin.. *Blood*, **2006**, 108, 1791-1791	2.2	
23	In Vivo Anti-Thrombotic Potency of Engineered Activated Protein C Variants.. *Blood*, **2007**, 110, 2704-2704	2.2	
22	Preservation of Beneficial TAFI Functions by an Activated Protein C Variant with Normal Cytoprotective Functions but Minimal Anticoagulant Activity.. *Blood*, **2007**, 110, 268-268	2.2	
21	Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg41 Site. *Blood*, **2019**, 134, 481-481	2.2	

20	Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo. *Blood*, **2019**, 134, 3632-3632	2.2
19	Novel R41Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for in Vivo Mechanisms of Action for Thrombin (IIa) and Activated Protein C (APC). *Blood*, **2014**, 124, 99-99	2.2
18	Acylcarnitines Are Novel Anticoagulant Lipids That Target Factor Xa and That Are Reduced in Plasma of Venous Thrombosis Patients Based on Untargeted and Targeted Metabolomics. *Blood*, **2014**, 124, 2797-2797	2.2
17	Coagulation Factor V Mediates Inhibition of Tissue Factor Signaling By Activated Protein C. *Blood*, **2015**, 126, 216-216	2.2
16	Role of Protein S and Gas6 in the Development of Purpura Fulminans. *Blood*, **2015**, 126, 1042-1042	2.2
15	Plasma Constitutive Serum Amyloid A4 Is Procoagulant and Is Elevated in Venous Thrombosis Patients. *Blood*, **2015**, 126, 3486-3486	2.2
14	Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells. *Blood*, **2016**, 128, 808-808	2.2
13	Novel R41Q- and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke. *Blood*, **2016**, 128, 13-13	2.2
12	Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2). *Blood*, **2008**, 112, 695-695	2.2
11	Factor V as Anticoagulant Cofactor for Activated Protein C in Factor Va Inactivation. *Blood*, **2008**, 112, 3075-3075	2.2
10	Lyso-Sulfatide Binds Factor Xa and Potently Inhibits Thrombin Generation.. *Blood*, **2010**, 116, 1130-1130	2.2
9	Novel Infrared Fluorescence Methodology Defines An Essential Role for Endothelial Protein C Receptor (EPCR) for Protection Against Vascular Leakage In Inflammation. *Blood*, **2010**, 116, 653-653	2.2
8	Warfarin Untargeted Metabolomics Study Identifies Novel Procoagulant Ethanolamide Lipids. *Blood*, **2011**, 118, 1200-1200	2.2
7	In Vitro and in Vivo Neutralization of Murine Activated Protein C. *Blood*, **2012**, 120, 3364-3364	2.2
6	Protection Against Vascular Leakage in Vivo by a Peptide Mimetic of the Novel Tethered Ligand Generated by Non-Canonical Cleavage of Protease Activated Receptor 1 by Activated Protein C. *Blood*, **2012**, 120, 497-497	2.2
5	Activated Protein C Cytoprotective Signaling in Endothelial Cells Involves apoER2 and Disabled-1. *Blood*, **2012**, 120, 1102-1102	2.2
4	Superior in Vivo Hemostatic Properties of an Engineered Factor Va Variant for Hemophilia Mice. *Blood*, **2012**, 120, 17-17	2.2
3	An Engineered Factor Fva Prevents Bleeding Induced By Anticoagulant Wild Type Activated Protein C. *Blood*, **2013**, 122, 203-203	2.2

2	Activation-Resistant Homozygous Protein C R229W Mutation Causing Familial Perinatal Intracranial Hemorrhage. *Blood*, **2013**, 122, 3587-3587	2.2
1	Overview on Blood Coagulation Proteins **1984**, 39-55	